Bausch Health skyrockets 27% after saying it will spin off its eye-care business (BHC) | Markets Insider

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 60 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 27%
  • Publisher: 51%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

Bausch Health skyrockets 27% after saying it will spin off its eye-care business

skyrocketed as much as 27% in premarket trading Thursday after the company announced its intention to spin off its eye-care business.

The pharmaceutical company plans to separate its Bausch + Lomb brand and portfolio of eye products into an independent and publicly traded company,"We are committed to taking action to unlock what we see as unrecognized value in Bausch Health shares, and we believe that separating our business into two highly focused, stand-alone companies is the way to accomplish that goal," said Joseph Papa, CEO of Bausch...

The spinoff will result in two companies — the eye care business, and a"diversified pharmaceutical company with leading positions in gastroenterology, aesthetics/ dermatology, neurology, and international pharmaceuticals," the company said. Tom Marsico's global stock fund has trounced its benchmark for 13 years — and returned 28 times its peers in 2020. Here's what he's been buying, and the beaten-down stocks he plans to grab after the pandemic.

The eye-care unit had $3.7 billion in revenue last year, where the rest of the company brought in about $4.9 billion, the company said. The spinoff will return the eye-care business to an independent company, which it was before Valeant Pharmaceuticals International

 

コメントありがとうございます。コメントは審査後に公開されます。

Hey, interested in talking to someone who bauschhealth denied patient assistance for a US $56k/ year drug?

What else do they do?

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 729. in JP

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Bausch Health to Spin Off Eye-Care BusinessBausch Health said it plans to spin off its faster-growing eye-care business from its core pharmaceutical operations, breaking apart a company previous management had built through such acquisitions. from Ye Olden Days $BHC $tsla $msft $googl $apo $lb currently down more than 86 percent from an August 2015 high of $262.52 and fell as low as $26.11 last week. This should give some insight into its accounting fraud. Interested in talking to someone who was denied patient assistance by bauschhealth for a US $56k/year drug?
ソース: WSJ - 🏆 98. / 63 続きを読む »